LXRX
Income statement / Annual
Last year (2024), Lexicon Pharmaceuticals, Inc.'s total revenue was $31.08 M,
an increase of 2,481.48% from the previous year.
In 2024, Lexicon Pharmaceuticals, Inc.'s net income was -$200.40 M.
See Lexicon Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$31.08 M |
$1.20 M |
$139,000.00 |
$298,000.00 |
$24.00 M |
$322.07 M |
$63.21 M |
$90.34 M |
$83.34 M |
$130.01 M |
| Cost of Revenue |
$616,000.00
|
$85,000.00
|
$427,000.00
|
$55.05 M
|
$1.93 M
|
$3.23 M
|
$2.49 M
|
$1.90 M
|
$163.97 M
|
$95.19 M
|
| Gross Profit |
$30.47 M
|
$1.12 M
|
-$288,000.00
|
-$54.75 M
|
$22.07 M
|
$318.84 M
|
$60.72 M
|
$88.44 M
|
-$80.64 M
|
$34.83 M
|
| Gross Profit Ratio |
0.98
|
0.93
|
-2.07
|
-183.72
|
0.92
|
0.99
|
0.96
|
0.98
|
-0.97
|
0.27
|
| Research and Development Expenses |
$84.48 M
|
$58.89 M
|
$52.82 M
|
$55.05 M
|
$153.62 M
|
$91.92 M
|
$100.24 M
|
$156.81 M
|
$178.15 M
|
$95.19 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$48.08 M
|
$0.00
|
$0.00
|
$0.00
|
$63.75 M
|
$66.20 M
|
$43.04 M
|
$23.84 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$143.10 M
|
$113.98 M
|
$48.08 M
|
$32.34 M
|
$47.23 M
|
$56.84 M
|
$63.75 M
|
$66.20 M
|
$43.04 M
|
$23.84 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.60 M
|
$28.64 M
|
$0.00
|
$1.95 M
|
$2.29 M
|
$572,000.00
|
| Operating Expenses |
$227.58 M
|
$172.87 M
|
$100.90 M
|
$87.39 M
|
$200.85 M
|
$148.76 M
|
$164.00 M
|
$223.02 M
|
$221.20 M
|
$119.02 M
|
| Cost And Expenses |
$228.20 M
|
$172.95 M
|
$100.90 M
|
$87.39 M
|
$202.78 M
|
$151.99 M
|
$166.49 M
|
$224.92 M
|
$221.20 M
|
$119.02 M
|
| Interest Income |
$12.29 M
|
$7.73 M
|
$1.60 M
|
$134,000.00
|
$2.77 M
|
$3.35 M
|
$3.51 M
|
$1.95 M
|
$2.29 M
|
$572,000.00
|
| Interest Expense |
$15.58 M
|
$13.10 M
|
$2.78 M
|
$802,000.00
|
$14.54 M
|
$20.68 M
|
$20.78 M
|
$6.98 M
|
$6.57 M
|
$6.72 M
|
| Depreciation & Amortization |
$534,000.00
|
$554,000.00
|
$427,000.00
|
$292,000.00
|
$2.93 M
|
$3.65 M
|
$3.68 M
|
$3.40 M
|
$2.06 M
|
$727,000.00
|
| EBITDA |
-$184.29 M |
-$163.46 M |
-$98.74 M |
-$86.66 M |
-$41.10 M |
$173.74 M |
-$96.09 M |
-$125.27 M |
-$125.82 M |
$11.72 M |
| EBITDA Ratio |
-5.93
|
-135.77
|
-713.41
|
-291.8
|
-7.34
|
0.54
|
-1.58
|
-1.47
|
-1.63
|
0.09
|
| Operating Income Ratio |
-6.34
|
-142.65
|
-724.89
|
-292.25
|
-7.45
|
0.44
|
-1.63
|
-1.51
|
-1.65
|
0.01
|
| Total Other Income/Expenses Net |
-$3.29 M
|
-$5.37 M
|
-$1.18 M
|
-$668,000.00
|
-$10.77 M
|
-$17.33 M
|
-$17.27 M
|
-$5.03 M
|
-$4.27 M
|
-$6.15 M
|
| Income Before Tax |
-$200.40 M
|
-$177.12 M
|
-$101.94 M
|
-$87.76 M
|
-$58.57 M
|
$124.12 M
|
-$120.55 M
|
-$141.71 M
|
-$141.43 M
|
-$4.68 M
|
| Income Before Tax Ratio |
-6.45
|
-147.11
|
-733.41
|
-294.49
|
-2.44
|
0.39
|
-1.91
|
-1.57
|
-1.7
|
-0.04
|
| Income Tax Expense |
$0.00
|
$0.00
|
$1.18 M
|
$510,000.00
|
$11.61 M
|
-$6.01 M
|
$3.51 M
|
-$12.66 M
|
$4.51 M
|
$6.00 M
|
| Net Income |
-$200.40 M
|
-$177.12 M
|
-$103.13 M
|
-$88.27 M
|
-$70.18 M
|
$130.13 M
|
-$120.55 M
|
-$129.05 M
|
-$141.43 M
|
-$4.68 M
|
| Net Income Ratio |
-6.45
|
-147.11
|
-741.93
|
-296.2
|
-2.92
|
0.4
|
-1.91
|
-1.43
|
-1.7
|
-0.04
|
| EPS |
-0.63 |
-0.8 |
-0.62 |
-0.61 |
-0.63 |
1.23 |
-1.14 |
-1.23 |
-1.36 |
-0.0452 |
| EPS Diluted |
-0.63 |
-0.8 |
-0.62 |
-0.61 |
-0.63 |
1.11 |
-1.14 |
-1.23 |
-1.36 |
-0.0452 |
| Weighted Average Shares Out |
$320.03 M
|
$221.13 M
|
$165.73 M
|
$145.65 M
|
$110.84 M
|
$106.22 M
|
$105.74 M
|
$105.12 M
|
$103.86 M
|
$103.59 M
|
| Weighted Average Shares Out Diluted |
$320.03 M
|
$221.13 M
|
$165.73 M
|
$145.65 M
|
$110.84 M
|
$116.75 M
|
$105.83 M
|
$105.24 M
|
$103.86 M
|
$103.59 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
